港股異動 | 都市麗人(2298.HK)漲超6% 獲主要股東及主席鄭耀南增持2.8萬股
格隆匯6月28日丨都市麗人(2298.HK)高開高走,一度大漲12%至1.2港元,現報1.14港元,漲幅收窄至6.54%,最新市值25億港元。都市麗人上週五(25日)晚間發公吿稱,公司獲公司主要股東及主席鄭耀南吿知,其已於今年6月23日及6月24日按每股1.05港元的平均價格從市場上購買合共2.8萬股公司普通股。該等股份相當於公吿日期公司已發行股本總額約0.0012%。鄭耀南也曾於今年5月31日及6月1日購入合共305.4萬股股份。合共計算,鄭耀南購買了308.2萬股份相當於公吿日期公司已發行股本總額約0.14%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.